Press release
Investigation announced for Long-Term Investors in shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc (NASDAQ: KPRX, formerly NASDAQ: EYEG)
An investigation for investors in Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc.
Investors who purchased shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc (NASDAQ: KPRX, formerly NASDAQ: EYEG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc (NASDAQ: KPRX, formerly NASDAQ: EYEG) concerning whether a series of statements by Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Salt Lake City, UT based Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $2.68 million in 2019 to $0.012 million in 2020, and that its Net Loss increased from $7.09 million in 2019 to $8.17 million in 2020.
Shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc (NASDAQ: KPRX, formerly NASDAQ: EYEG) declined from over $12 per share in late 2019 to as low as $1.20 per share on December 6, 2021.
Those who purchased shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc (NASDAQ: KPRX, formerly NASDAQ: EYEG) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc (NASDAQ: KPRX, formerly NASDAQ: EYEG) here
News-ID: 2490683 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Pharmaceuticals
Cystic fibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | Veron …
Cystic fibrosis therapies, such as TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others, are expected to boost the Cystic fibrosis Market in the upcoming years.
DelveInsight has launched a new report on "Cystic fibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cystic fibrosis, historical and forecasted epidemiology as well as the Cystic fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Gastritis Drugs Market Size Report 2032 | Regeneron Pharmaceuticals, Sanofi, Han …
DelveInsight's "Gastritis Market Insights, Epidemiology, and Market Forecast -2032" report delivers an in-depth understanding of the Gastritis, historical and forecasted epidemiology as well as the Gastritis market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Key Takeaways from the Gastritis Market Research Report
• The increase in Gastritis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging…
Generic Pharmaceuticals Market Set for More Growth| Hikma Pharmaceuticals, Emcur …
Advance Market Analytics published a new research publication on "Generic Pharmaceuticals Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Generic Pharmaceuticals market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample Copy of…
Global Halal Pharmaceuticals Market 2019 - CCM Pharmaceuticals, Pharmaniaga, Ros …
This new report by Eon Market Research, titled “Global Halal Pharmaceuticals Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Halal Pharmaceuticals industry at a global as well as regional and country level. Key facts analyzed in this report include the Halal Pharmaceuticals market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study…
Topical Antibiotic Pharmaceuticals Market 2016-2026 | Teva Pharmaceuticals, Perr …
Topical antibiotics are applied to a certain area of the skin to kill infections. Application of topical antibiotics has a number of advantages upon comparison of systemic delivery in the treatment of skin infections. Skin and soft tissue infections (SSTIs) involve microbial invasion of the skin and underlying soft tissues infections are one of the most commonly occurring conditions amongst people. Most of these infections are minor and chronic in…
Lipid Disorder Treatment Market to 2017 - 2026: Teva Pharmaceuticals, Mylan Phar …
Researchmoz added Most up-to-date research on "Lipid Disorder Treatment Market - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026" to its huge collection of research reports
Extensive research report on global lipid disorders treatment market skilfully crafted by Transparency Market Research depicts the current as well as future scenario of various drugs used to treat lipid disorders. The research study includes analysis on key developments that are…
